The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia

Published:2009-03 Issue:6 Volume:144 Page:848-855
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Lapalombella Rosa,Gowda Aruna,Joshi Trupti,Mehter Najma,Cheney Carolyn,Lehman Amy,Chen Ching-Shih,Johnson Amy J.,Caligiuri Michael A.,Tridandapani Susheela,Muthusamy Natarajan,Byrd John C.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2008.07548.x/fullpdf

Reference35 articles.

1. SGN-40 (Anti-huCD40 mAb) monotherapy induces durable objective responses in patients with relapsed aggressive non-Hodgkin’s lymphoma: evidence of antitumor activity from a phase I study;Advani;Blood (ASH Annual Meeting Abstracts),2006

2. Higher doses of lenalidomide are associated with unacceptable toxicity including life threatening tumor flare in patients with chronic lymphocytic leukemia;Andritsos;Journal of Clinical Oncology,2008

3. The CD40 antigen and its ligand;Banchereau;Annual Review of Immunology,1994

4. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712);Byrd;Blood,2003

5. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011;Byrd;Blood,2005

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. APX005M, a CD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application;Cancer Immunology, Immunotherapy;2021-01-03

2. Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2020-09-23

3. A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL);Leukemia & Lymphoma;2018-10-02

4. Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience;Drugs;2017-02-16

5. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia;Seminars in Oncology;2016-04